JOP20200119A1 - مركبات مساعد مشترك من gip وglp-1 - Google Patents

مركبات مساعد مشترك من gip وglp-1

Info

Publication number
JOP20200119A1
JOP20200119A1 JOP/2020/0119A JOP20200119A JOP20200119A1 JO P20200119 A1 JOP20200119 A1 JO P20200119A1 JO P20200119 A JOP20200119 A JO P20200119A JO P20200119 A1 JOP20200119 A1 JO P20200119A1
Authority
JO
Jordan
Prior art keywords
gip
glp
agonist compounds
peptide
glucagon
Prior art date
Application number
JOP/2020/0119A
Other languages
English (en)
Inventor
Alsina-Fernandez Jorge
Coskun Tamer
Krister Bokvist Bengt
Chadwick Cummins Robert
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55315708&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20200119(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of JOP20200119A1 publication Critical patent/JOP20200119A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

يتعلق الاختراع الحالي بمركبات محاكية لبببتيد إنكرتين مزدوج تحفز مستقبلات كل من البولي ببتيد المُفرز للأنسولين المعتمد على الجلوكوز البشري (GIP) والببتيد 1 الشبيه بالجلوكاجون (GLP-1)، ويمكن أن تكون مفيدة في علاج مرض السكري من النوع 2 (T2D).
JOP/2020/0119A 2015-01-09 2015-01-09 مركبات مساعد مشترك من gip وglp-1 JOP20200119A1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562101488P 2015-01-09 2015-01-09

Publications (1)

Publication Number Publication Date
JOP20200119A1 true JOP20200119A1 (ar) 2017-06-16

Family

ID=55315708

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2020/0119A JOP20200119A1 (ar) 2015-01-09 2015-01-09 مركبات مساعد مشترك من gip وglp-1
JOP/2015/0334A JO3575B1 (ar) 2015-01-09 2015-12-22 مركبات مساعد مشترك من gip وglp-1

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2015/0334A JO3575B1 (ar) 2015-01-09 2015-12-22 مركبات مساعد مشترك من gip وglp-1

Country Status (45)

Country Link
US (1) US9474780B2 (ar)
EP (2) EP3242887B1 (ar)
JP (3) JP6219534B2 (ar)
KR (4) KR102330764B1 (ar)
CN (2) CN112608377B (ar)
AR (1) AR103242A1 (ar)
AU (1) AU2016205435B2 (ar)
CA (1) CA2973352C (ar)
CL (1) CL2017001760A1 (ar)
CO (1) CO2017006737A2 (ar)
CR (1) CR20170310A (ar)
CY (1) CY1122028T1 (ar)
DK (1) DK3242887T3 (ar)
DO (1) DOP2017000153A (ar)
EA (3) EA035055B1 (ar)
EC (1) ECSP17043648A (ar)
ES (1) ES2747928T3 (ar)
FI (1) FIC20230005I1 (ar)
FR (1) FR23C1006I2 (ar)
HR (1) HRP20191614T1 (ar)
HU (2) HUE045860T2 (ar)
IL (3) IL252499B (ar)
JO (2) JOP20200119A1 (ar)
LT (2) LT3242887T (ar)
MA (2) MA50422A (ar)
MD (1) MD3242887T2 (ar)
ME (1) ME03494B (ar)
MX (2) MX2017008927A (ar)
MY (1) MY193616A (ar)
NL (1) NL301217I2 (ar)
NO (1) NO2023005I1 (ar)
NZ (1) NZ732000A (ar)
PE (1) PE20170954A1 (ar)
PH (1) PH12017501252A1 (ar)
PL (1) PL3242887T3 (ar)
PT (1) PT3242887T (ar)
RS (1) RS59146B1 (ar)
SG (1) SG11201705603YA (ar)
SI (1) SI3242887T1 (ar)
SV (1) SV2017005453A (ar)
TN (1) TN2017000198A1 (ar)
TW (1) TWI582109B (ar)
UA (1) UA118239C2 (ar)
WO (1) WO2016111971A1 (ar)
ZA (1) ZA201703930B (ar)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456589B (zh) 2013-12-18 2020-07-07 斯克利普斯研究所 修饰的治疗剂、订合的肽脂质缀合物及其组合物
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
WO2018104263A1 (en) 2016-12-06 2018-06-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
WO2018213151A1 (en) * 2017-05-18 2018-11-22 Merck Sharp & Dohme Corp. Pharmaceutical formulation comprising incretin-insulin conjugates
TWI810937B (zh) * 2017-12-21 2023-08-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
TWI744579B (zh) * 2017-12-21 2021-11-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
WO2019140030A1 (en) 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
CA3097939A1 (en) * 2018-05-04 2019-11-07 Novo Nordisk A/S Gip derivatives and uses thereof
TWI705820B (zh) * 2018-06-22 2020-10-01 美商美國禮來大藥廠 Gip/glp1促效劑組合物
CA3107108A1 (en) * 2018-07-23 2020-01-30 Eli Lilly And Company Method of using a gip/glp1 co-agonist for diabetes
SG11202100128UA (en) * 2018-07-23 2021-02-25 Lilly Co Eli Gip/glp1 co-agonist compounds
CA3107344A1 (en) 2018-07-23 2020-01-30 Eli Lilly And Company Methods of using a gip/glp1 co-agonist for therapy
JP6564539B1 (ja) 2018-09-14 2019-08-21 長瀬産業株式会社 スルホン酸化合物によるペプチド精製方法
WO2020067575A1 (en) 2018-09-24 2020-04-02 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
TWI799680B (zh) * 2019-01-29 2023-04-21 美商美國禮來大藥廠 製備gip/glp1雙重促效劑之方法
KR20220020879A (ko) 2019-06-12 2022-02-21 에스크진 파마, 아이엔씨. 새로운 il-15 프로드럭 및 이를 사용하는 방법
TWI764209B (zh) 2019-08-01 2022-05-11 美商美國禮來大藥廠 Gipr促效劑化合物
WO2021034815A1 (en) 2019-08-19 2021-02-25 Eli Lilly And Company Methods of making incretin analogs
US20230000950A1 (en) 2019-10-04 2023-01-05 Hanmi Pharm. Co., Ltd. Composition comprising glucagon and glp-1 and gip receptor dual agonist and therapeutic use of same
CN110684082B (zh) * 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
TWI795698B (zh) * 2019-12-18 2023-03-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
MX2022009149A (es) * 2020-01-23 2022-12-15 Lilly Co Eli Compuestos coagonistas de gip/glp1.
TW202228762A (zh) * 2020-01-30 2022-08-01 美商美國禮來大藥廠 提派肽(tirzepatide)之治療用途
CN111253475B (zh) * 2020-02-18 2021-03-09 江苏诺泰澳赛诺生物制药股份有限公司 Glp-1激动多肽化合物及其盐与合成方法及用途
CN115884982A (zh) 2020-03-06 2023-03-31 赛诺菲 作为选择性gip受体激动剂的肽
CN113493503B (zh) * 2020-04-08 2022-08-05 浙江道尔生物科技有限公司 一种肠促胰岛素类似物及其制备方法和用途
TW202216746A (zh) * 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
CN116157414A (zh) 2020-07-22 2023-05-23 诺和诺德股份有限公司 Glp-1和gip受体共激动剂
KR102446310B1 (ko) * 2020-07-22 2022-09-23 노보 노르디스크 에이/에스 경구 전달에 적합한 glp-1 및 gip 수용체에서의 공-작용제
CN115925995A (zh) * 2020-09-30 2023-04-07 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
WO2022079639A1 (en) 2020-10-17 2022-04-21 Sun Pharmaceutical Industries Limited Glp-1/gip dual agonists
WO2022117056A1 (zh) * 2020-12-02 2022-06-09 南京明德新药研发有限公司 含内酰胺修饰的多肽类化合物
MX2023008330A (es) * 2021-01-20 2024-01-18 Viking Therapeutics Inc Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos.
CA3208873A1 (en) * 2021-02-17 2022-08-25 Mathijs Christiaan Michael BUNCK Gip/glp1 dual agonist therapeutic methods
CA3208208A1 (en) 2021-02-17 2022-08-25 Mathijs Christiaan Michael BUNCK Tirzepatide therapeutic methods
JP2024511107A (ja) * 2021-03-25 2024-03-12 ブライトジーン バイオ－メディカル テクノロジー カンパニー リミテッド Ｇｉｐとｇｌｐ－１の二重受容体作動薬、医薬組成物および使用
CN117642153A (zh) 2021-05-07 2024-03-01 伊莱利利公司 易蚀片剂
JP2024516070A (ja) * 2021-05-28 2024-04-12 広東衆生睿創生物科技有限公司 ポリペプチドの調製およびその使用
CN117440964A (zh) * 2021-06-01 2024-01-23 南京知和医药科技有限公司 一种glp-1r和gipr双重靶向激动作用的多肽衍生物及其制备方法和用途
WO2022262825A1 (zh) * 2021-06-18 2022-12-22 南京明德新药研发有限公司 含内酰胺桥的多肽化合物
WO2023031455A1 (en) 2021-09-06 2023-03-09 Sanofi Sa New peptides as potent and selective gip receptor agonists
JP2024508096A (ja) * 2021-09-15 2024-02-22 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023084118A1 (en) 2021-11-15 2023-05-19 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023089594A1 (en) 2021-11-22 2023-05-25 Sun Pharmaceutical Industries Limited Process for the preparation of tirzepatide or pharmaceutically acceptable salt thereof
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
WO2023193727A1 (zh) * 2022-04-07 2023-10-12 广东众生睿创生物科技有限公司 多肽在制备治疗和/或预防糖尿病及肥胖症及其相关疾病药物中的制药用途
WO2024006662A1 (en) 2022-06-30 2024-01-04 Eli Lilly And Company Tirzepatide compositions and use
EP4299052A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and a permeation enhancer
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
CN117402219A (zh) * 2022-07-13 2024-01-16 杭州中美华东制药有限公司 Glp-1/gip双激动剂及其制备方法和用途
WO2024020388A1 (en) * 2022-07-20 2024-01-25 Viking Therapeutics, Inc. Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders
WO2024050289A1 (en) 2022-08-29 2024-03-07 Eli Lilly And Company Compositions for oral delivery
WO2024059674A1 (en) 2022-09-15 2024-03-21 Eli Lilly And Company Gip and glp-1 dual agonist compounds
WO2024061310A1 (zh) * 2022-09-23 2024-03-28 博瑞生物医药（苏州）股份有限公司 一种glp-1和gip双受体激动剂药物组合物及其用途
WO2024077149A2 (en) 2022-10-05 2024-04-11 Eli Lilly And Company Peptides for incretin synthesis
CN116832141B (zh) * 2023-06-06 2024-02-09 诺博泰科(成都)生物科技有限公司 一种用于治疗糖尿病的glp-1、gip和gcg受体三激动多肽化合物
CN116693652B (zh) * 2023-08-02 2024-01-05 北京惠之衡生物科技有限公司 一种glp-1/gip受体双重激动剂衍生物及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272652A1 (en) * 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US20080171695A1 (en) * 2005-02-02 2008-07-17 Novo Nordisk A/S Insulin Derivatives
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
WO2010016938A2 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Glucose-dependent insulinotropic polypeptide analogues
CN102149411A (zh) 2008-09-12 2011-08-10 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
CN101367873B (zh) * 2008-10-08 2011-05-04 南开大学 一种改构的胰高血糖素样肽-1的类似物和修饰物及其应用
SG172291A1 (en) 2008-12-19 2011-07-28 Univ Indiana Res & Tech Corp Amide based glucagon superfamily peptide prodrugs
GB0917072D0 (en) * 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
RU2012136450A (ru) 2010-01-27 2014-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Конъюгаты антагонист глюкагона - агонист gip и композиции для лечения метаболических расстройств и ожирения
AR080592A1 (es) * 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
KR101091041B1 (ko) * 2010-07-29 2011-12-09 고려대학교 산학협력단 새로운 재조합 글루코스 의존성 인슐린분비 펩타이드(ｒｃＧＩＰ) 작용제 및 그 용도
EA201390941A1 (ru) 2010-12-22 2013-12-30 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Аналоги глюкагона, проявляющие активность на рецепторе gip
CA2822617A1 (en) * 2010-12-22 2012-06-28 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
US9790262B2 (en) 2011-04-05 2017-10-17 Longevity Biotech, Inc. Compositions comprising glucagon analogs and methods of making and using the same
US9453062B2 (en) 2011-06-10 2016-09-27 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
EP2720711A1 (en) 2011-06-15 2014-04-23 Novo Nordisk A/S Multi substituted insulins
JP6352806B2 (ja) * 2011-09-23 2018-07-04 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
EP2793931A2 (en) * 2011-12-23 2014-10-29 Zealand Pharma A/S Glucagon analogues
WO2013164483A1 (en) * 2012-05-03 2013-11-07 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
MX2014015558A (es) * 2012-06-21 2015-03-05 Univ Indiana Res & Tech Corp Analogos de glucagon que exhiben actividad del receptor gip.
JP2015536314A (ja) 2012-10-17 2015-12-21 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 成長ホルモン送達のための脂肪酸アシル化アミノ酸
UA116553C2 (uk) 2012-12-21 2018-04-10 Санофі Пептидна сполука - агоніст рецептора glp-1 i glp
UA118558C2 (uk) 2013-05-28 2019-02-11 Такеда Фармасьютікал Компані Лімітед Пептидна сполука

Also Published As

Publication number Publication date
EA201892057A1 (ru) 2019-02-28
KR102330764B1 (ko) 2021-11-25
NL301217I2 (nl) 2023-04-04
EA202090392A3 (ru) 2020-08-31
CN112608377B (zh) 2024-02-13
CL2017001760A1 (es) 2018-03-16
US20160199438A1 (en) 2016-07-14
CR20170310A (es) 2017-08-17
IL276492B (en) 2021-04-29
HUE045860T2 (hu) 2020-01-28
HRP20191614T1 (hr) 2019-12-13
TWI582109B (zh) 2017-05-11
NO2023005I1 (no) 2023-02-02
IL281545A (en) 2021-05-31
IL252499B (en) 2020-08-31
TW201636362A (zh) 2016-10-16
ZA201703930B (en) 2019-06-26
CY1122028T1 (el) 2020-10-14
MA41315A (fr) 2017-11-15
CA2973352C (en) 2019-03-26
EA201791281A1 (ru) 2017-11-30
EA031591B1 (ru) 2019-01-31
EP3242887B1 (en) 2019-08-14
FIC20230005I1 (fi) 2023-02-02
EA202090392A2 (ru) 2020-05-31
DOP2017000153A (es) 2017-07-15
MA50422A (fr) 2020-08-26
KR20170092661A (ko) 2017-08-11
ME03494B (me) 2020-01-20
JP2018052933A (ja) 2018-04-05
BR112017010596A2 (pt) 2018-03-06
FR23C1006I1 (fr) 2023-03-24
CN107207576B (zh) 2020-11-24
KR20210145311A (ko) 2021-12-01
EP3242887A1 (en) 2017-11-15
DK3242887T3 (da) 2019-09-02
HUS2300006I1 (hu) 2023-02-28
CA2973352A1 (en) 2016-07-14
MD3242887T2 (ro) 2019-11-30
JP6545766B2 (ja) 2019-07-17
RS59146B1 (sr) 2019-09-30
ES2747928T3 (es) 2020-03-12
KR20230023822A (ko) 2023-02-17
LT3242887T (lt) 2019-11-11
CN112608377A (zh) 2021-04-06
MX2021005835A (es) 2021-07-15
UA118239C2 (uk) 2018-12-10
CO2017006737A2 (es) 2017-09-29
IL276492A (en) 2020-09-30
KR101957620B1 (ko) 2019-03-13
PH12017501252A1 (en) 2017-10-30
AR103242A1 (es) 2017-04-26
KR20190026967A (ko) 2019-03-13
PT3242887T (pt) 2019-10-29
JP2017507124A (ja) 2017-03-16
MY193616A (en) 2022-10-20
LTPA2023504I1 (ar) 2023-02-27
PE20170954A1 (es) 2017-07-13
MA41315B1 (fr) 2019-11-29
AU2016205435A1 (en) 2017-06-08
JP6219534B2 (ja) 2017-10-25
SI3242887T1 (sl) 2019-10-30
US9474780B2 (en) 2016-10-25
CN107207576A (zh) 2017-09-26
EA035055B1 (ru) 2020-04-22
SG11201705603YA (en) 2017-08-30
FR23C1006I2 (fr) 2024-01-05
EP3597662A1 (en) 2020-01-22
TN2017000198A1 (en) 2018-10-19
NZ732000A (en) 2018-11-30
NZ748274A (en) 2022-03-25
JP6754867B2 (ja) 2020-09-16
AU2016205435B2 (en) 2018-03-29
JP2019203000A (ja) 2019-11-28
MX2017008927A (es) 2017-10-11
IL252499A0 (en) 2017-07-31
WO2016111971A1 (en) 2016-07-14
NL301217I1 (ar) 2023-02-15
PL3242887T3 (pl) 2020-02-28
JO3575B1 (ar) 2020-07-05
SV2017005453A (es) 2018-08-27
ECSP17043648A (es) 2017-11-30

Similar Documents

Publication Publication Date Title
PH12017501252A1 (en) Gip and glp-1 co-agonist compounds.
SA518391903B1 (ar) معاضد مستقبل جلوكاجون/الببتيد 1 المشابه للجلوكاجون/البولي ببتيد المحب للأنسولين المعتمد على الجلوكوز الثلاثي
MY197569A (en) Gip/glp1 co-agonist compounds
EA035466B9 (ru) Соединения и способы на основе двойного агониста гип и гпп-1
NZ740644A (en) Glucagon receptor agonists
MX2019006260A (es) Agonistas de glucagon/peptido similar al glucagon de tipo 1 (glp-1) para el tratamiendo de la obesidad.
EP3922260A3 (en) Insulin receptor partial agonists and glp-1 analogues
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
MX2022001137A (es) Compuestos agonistas de gipr.
MX2015016715A (es) Agonistas del receptor de la vitamina d para tratar enfermedades que afectan a la actividad de cxcl12.
MX2017000972A (es) Nuevos moduladores del receptor de peptido similar a glucagon 1 (glp-1).
EA201592281A1 (ru) Новые модуляторы рецептора glp-1
MX2023002906A (es) Agonistas duales glp-1/gip.
MX2021005724A (es) Tratamiento combinado contra nafld y nash.
MX2022016032A (es) Agonistas dobles de glp-1/gip de accion prolongada.
JOP20220153A1 (ar) نظائر الإنكرتين واستخداماتها
EP4043026A4 (en) GLUCAGON, GLP-1 RECEPTOR AND DGIP RECEPTOR DUAL AGONIST COMPOSITION AND THERAPEUTIC USE THEREOF
MX2015009433A (es) Polipeptidos novedosos que tienen actividad liberadora de hormonas de la saciedad.
WO2014023923A3 (fr) Traitement de l'arthrose par les hormones incrétines ou leurs analogues